Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy

In patients with hypogammaglobulinemia secondary to chronic lymphocytic leukemia (CLL) or multiple myeloma (MM), intravenous immune globulin (IVIg) may be administered to reduce the risk of infection. Since 2013, IVIg products have carried a boxed safety warning about the risk of thromboembolic even...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Ammann, Eric M., Jones, Michael P., Link, Brian K., Carnahan, Ryan M., Winiecki, Scott K., Torner, James C., McDowell, Bradley D., Fireman, Bruce H., Chrischilles, Elizabeth A.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2016
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4713161/
https://ncbi.nlm.nih.gov/pubmed/26443622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647552
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items